REGENXBIO Inc.
US ˙ NasdaqGS ˙ US75901B1070

SecurityRGNX / REGENXBIO Inc.
InstitutionQube Research & Technologies Ltd
Latest Disclosed Ownership1,310,493 shares
Latest Disclosed Value $ 10,981,931
Qube Research & Technologies Ltd reports 196.03% increase in ownership of RGNX / REGENXBIO Inc.

On May 15, 2026 - Qube Research & Technologies Ltd filed a 13F-HR form disclosing ownership of 1,310,493 shares of REGENXBIO Inc. (US:RGNX) valued at $10,981,931 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 442,690 shares of REGENXBIO Inc.. This represents a change in shares of 196.03% during the quarter. The current value of the position is $8,767,198 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F REGENXBIO COM 75901B107 1,310,493 867,803 196.03 10,982 72.28 0.0122
2026-02-17 2025-12-31 13F REGENXBIO COM 75901B107 442,690 157,859 55.42 6,375 131.95 0.0065
2025-11-14 2025-09-30 13F REGENXBIO COM 75901B107 284,831 -172,281 -37.69 2,749 -26.76 0.0028
2025-08-14 2025-06-30 13F REGENXBIO COM 75901B107 457,112 64,317 16.37 3,753 33.62 0.0038
2025-05-15 2025-03-31 13F REGENXBIO COM 75901B107 392,795 38,802 10.96 2,808 2.63 0.0033
2025-02-14 2024-12-31 13F REGENXBIO COM 75901B107 353,993 159,919 82.40 2,736 34.45 0.0036
2024-11-14 2024-09-30 13F REGENXBIO COM 75901B107 194,074 84,092 76.46 2,036 58.24 0.0030
2024-08-14 2024-06-30 13F REGENXBIO COM 75901B107 109,982 67,010 155.94 1,287 42.10 0.0020
2024-05-14 2024-03-31 13F REGENXBIO COM 75901B107 42,972 24,034 126.91 905 166.96 0.0014
2024-02-13 2023-12-31 13F REGENXBIO COM 75901B107 18,938 18,938 340 0.0007
2023-08-14 2023-06-30 13F REGENXBIO COM 75901B107 0 -43,491 -100.00 0 -100.00
2023-05-15 2023-03-31 13F REGENXBIO COM 75901B107 43,491 6,436 17.37 822 -2.14 0.0035
2023-02-14 2022-12-31 13F REGENXBIO COM 75901B107 37,055 37,055 840 0.0045
2021-08-13 2021-06-30 13F REGENXBIO COM 75901B107 0 -15,045 -100.00 0 -100.00
2021-05-14 2021-03-31 13F REGENXBIO COM 75901B107 15,045 15,045 513 0.0081
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.